GENPREX INC (GNPX) Stock Price, Quote, News and Overview
NASDAQ:GNPX - Nasdaq - US3724462037 - Common Stock - Currency: USD
GNPX Quote, Performance and Key Statistics
0.2848
+0.02 (+6.87%)
The current stock price of GNPX is 0.2848 USD. In the past month the price decreased by -16.73%. In the past year, price decreased by -87.11%.
GNPX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.39 | 329.14B | ||
| AMGN | AMGEN INC | 14.17 | 150.99B | ||
| GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
| ARGX | ARGENX SE - ADR | 330.52 | 37.54B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
| NTRA | NATERA INC | N/A | 20.79B | ||
| BIIB | BIOGEN INC | 7.22 | 17.39B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
Related stock screener links
About GNPX
Company Profile
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company is headquartered in Austin, Texas and currently employs 26 full-time employees. The company went IPO on 2018-03-29. The Company’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles. The Company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Using a different gene therapy delivery system, the Company is also developing its preclinical diabetes candidate GPX-002 using the same construct for both Type 1 diabetes and Type 2 diabetes. The company conducts preclinical research to explore how REQORSA may be administered in other solid tumors.
Company Info
GENPREX INC
1601 Trinity Street, Bldg. B, Suite 3.322
Austin TEXAS 78712 US
CEO: J. Rodney Varner
Employees: 21
Company Website: https://www.genprex.com/
Investor Relations: http://www.genprex.com/investors/
Phone: 15125377997
GENPREX INC / GNPX FAQ
What is the stock price of GENPREX INC today?
The current stock price of GNPX is 0.2848 USD. The price increased by 6.87% in the last trading session.
What is the ticker symbol for GENPREX INC stock?
The exchange symbol of GENPREX INC is GNPX and it is listed on the Nasdaq exchange.
On which exchange is GNPX stock listed?
GNPX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GENPREX INC stock?
7 analysts have analysed GNPX and the average price target is 7.65 USD. This implies a price increase of 2586.1% is expected in the next year compared to the current price of 0.2848. Check the GENPREX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GENPREX INC worth?
GENPREX INC (GNPX) has a market capitalization of 6.88M USD. This makes GNPX a Nano Cap stock.
How many employees does GENPREX INC have?
GENPREX INC (GNPX) currently has 21 employees.
What are the support and resistance levels for GENPREX INC (GNPX) stock?
GENPREX INC (GNPX) has a support level at 0.28 and a resistance level at 0.34. Check the full technical report for a detailed analysis of GNPX support and resistance levels.
Should I buy GENPREX INC (GNPX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GNPX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GNPX, evaluating the profitability, health, valuation and growth aspects
- GENPREX INC (GNPX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GENPREX INC (GNPX) Sales and EPS estimates to see what analysts future expectations are.
- GENPREX INC (GNPX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GENPREX INC (GNPX) Insider and Institutional Ownership to learn about the owners and their transactions.
- GENPREX INC (GNPX) Stock Chart to make your own analysis
- GENPREX INC (GNPX) Latest news and press-releases to stay up to date.
Does GENPREX INC (GNPX) stock pay dividends?
GNPX does not pay a dividend.
When does GENPREX INC (GNPX) report earnings?
GENPREX INC (GNPX) will report earnings on 2025-05-13, after the market close.
What is the Price/Earnings (PE) ratio of GENPREX INC (GNPX)?
GENPREX INC (GNPX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.07).
What is the Short Interest ratio of GENPREX INC (GNPX) stock?
The outstanding short interest for GENPREX INC (GNPX) is 1.15% of its float. Check the ownership tab for more information on the GNPX short interest.
GNPX Technical Analysis
GNPX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GNPX. The financial health of GNPX is average, but there are quite some concerns on its profitability.
GNPX Financial Highlights
Over the last trailing twelve months GNPX reported a non-GAAP Earnings per Share(EPS) of -9.07. The EPS increased by 60.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -518.59% | ||
| ROE | -1320.11% | ||
| Debt/Equity | 0 |
GNPX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to GNPX. The Buy consensus is the average rating of analysts ratings from 7 analysts.